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Background: We characterized the spectrum and etiology of hypogonadism in a cohort of Prader-Willi syndrome
(PWS) adolescents and adults.
Methods: Reproductive hormonal profiles and physical examination were performed on 19 males and 16 females ages
16–34 years with PWS. Gonadotropins, sex-steroids, inhibin B (INB) and anti-Mullerian hormone (AMH) were measured.
We defined 4 groups according to the relative contribution of central and gonadal dysfunction based on FSH and INB
levels: Group A: primary hypogonadism (FSH >15 IU/l and undetectable INB (<10 pg/ml); Group B: central
hypogonadism (FSH <0.5 IU/l, INB <10 pg/ml); Group C: partial gonadal & central dysfunction (FSH 1.5–15 IU/l,
INB >20 pg/ml); Group D: mild central and severe gonadal dysfunction (FSH 1.5–15 IU/l, INB< 10 pg/ml.
Results: There were 10, 8, 9 and 8 individuals in Groups A-D respectively; significantly more males in group A (9, 4, 4
and 2; P= 0.04). Significant differences between the groups were found in mean testosterone (P=0.04), AMH (P=0.003)
and pubic hair (P=0.04) in males and mean LH (P=0.003) and breast development (P=0.04) in females. Mean age,
height, weight, BMI and the distribution of genetic subtypes were similar within the groups.
Conclusions: Analysis of FSH and inhibin B revealed four distinct phenotypes ranging from primary gonadal to central
hypogonadism. Primary gonadal dysfunction was common, while severe gonadotropin deficiency was rare.
Longitudinal studies are needed to verify whether the individual phenotypes are consistent.Background
Prader-Willi syndrome (PWS), first described in 1956 [1]
is a neurodevelopmental disorder caused by the absence of
paternal expression of imprinted genes localized in the
15q11-q13 region. PWS is characterized by severe hypo-
tonia and feeding difficulties in infancy, an insatiable appe-
tite leading to severe obesity in childhood, short stature,
dysmorphic features and cognitive and behavioral pro-
blems [2-4]. Manifestations of hypogonadism in infancy
include genital hypoplasia in females and micropenis and/
or cryptorchidism in males [2,3]. Delayed and incomplete
pubertal development is documented in almost all patients
with PWS; however precocious puberty has also been
described [5]. Some females undergo spontaneous menar-
che but most have primary or secondary amenorrhea or
oligomenorrhea [6]. Pregnancies have been reported in* Correspondence: gevat@szmc.org.il
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reproduction in any medium, provided the orthree women with genetically documented PWS thus
demonstrating the variable degrees and expression of
hypogonadism in this condition [7,8]. No cases of paternity
have been described in PWS males.
Hypogonadism in PWS was generally considered to be
of central, hypothalamic origin [2,6,9,10]. We previously
reported that primary testicular dysfunction is a major
contributor to the hypogonadism seen in males with PWS
and that variable combinations of primary ovarian defect
and hypothalamic dysfunction contribute to the hypo-
gonadism in PWS women [11,12]. The heterogeneous pat-
terns of reproductive hormones indicate that some PWS
women may potentially be fertile, while others may require
hormone replacement therapy. Recently, Radicioni et al
confirmed the heterogeneity of reproductive hormone pro-
files in PWS [13].
In view of the physical and psycho-social consequences
of hypogonadism in this population, hormonal treatment
for affected individuals needs to be considered. There
are, however, no clear therapeutic guidelines for treating
hypogonadism in this population. The aim of the presentral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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reproductive phenotypes of PWS patients in order to
provide a basis for routine evaluation of gonadal function
and individual treatment options.
Methods
The procedure was approved by the local ethical commit-
tee. It was explained to patients and informed consent was
obtained from parents, guardians or adult patients.
Patients
Of the 112 (52 females) known PWS individuals in Israel,
almost all are treated in the multidisciplinary national re-
ferral clinic at Shaare Zedek Medical Center, Jerusalem.
In this report, we describe our findings in 35 adolescents
and adults (16 females) ages 16–34 years. The study
group includes 15 males and 14 females some of whose
hormonal data appear in our previous publications (11,
12). An additional 2 patients (aged 20 and 28 years)
refused to participate and a 21 year-old man was
excluded since he was treated with testosterone replace-
ment at the time of the study. No patient was treated
with sex hormones for at least six months prior to the
study. One 28 year-old man was treated with testoster-
one for several months but stopped the treatment due to
behavioral side effects 10 years before the study. One
20 year-old woman received progyluton [sequential es-
tradiol valerate 2 mg (11 tabs) and estradiol valerate
2 mg plus norgestrel 0.5 mg (11 tablets) (Schering AG/
Berlin, Germany)] for several years until 6 months prior
to the study. These two were excluded from analyses of
height, BMI and the degree of sexual development.
One woman was treated with l-thyroxine for acquired
primary hypothyroidism. Two women with diabetes mel-
litus were treated with insulin. Other medications
included risperdone in 5 women, selective serotonine-re-
uptake inhibitors (SSRIs) in 5 and topiramate in 2. Three
subjects (two men aged 27 and 28 and one woman aged
21 years) received growth hormone several years before
the study.
Clinical assessment and hormonal examinations
Pubertal development was evaluated using the Tanner
classification [14,15]. Serum concentrations of LH, FSH,
estradiol, testosterone, TSH, and prolactin were measured
using DxI 800 (Beckman Coulter Instruments Inc., USA).
Assay sensitivities were 0.1 IU/L, 0.1 IU/L, 15 pg/ml,
0.1 ng/ml, 0.03 U/ml, and 0.5 ng/ml, respectively. The es-
tradiol intra-assay coefficients of variation (CV) were 6.3–
15% for levels ≥40 pg/ml and 20% for levels <40 pg/ml.
Inter-assay and intra-assay CVs were less than 7% for other
measurements. Dehydroepiandrosterone sulfate (DHEAS),
androstenedione, and SHBG concentrations were mea-
sured using immunochemiluminescence on IMMULITE(Siemens, Diagnostic Product Corporation, Los Angeles,
CA). Assay sensitivities were 0.1 μg/dl, 0.3 ng/ml, and
0.02 nmol/l, respectively, and inter- and intraassay coeffi-
cients of variation were less than 10%.
Serum INB and AMH concentrations were measured
using highly sensitive two-site ELISAs (Diagnostic Sys-
tems Laboratories, Webster, TX). The assay sensitivities
were 7 pg/ml and 0.017 ng/ml, respectively. Inter- and
intra-assay coefficients of variation were 15 and 7% for
INB and 8.7 and 5.3% for AMH, respectively.
Published data from Esoterix Labs (Austin, TX) were
used as normal reference ranges of data for hormone
levels in adolescents and young adults except for AMH,
INB, and SHBG [16]. Appropriate control data for
AMH, INB, and SHBG were obtained from published
reference data [17-21].
We utilized FSH and INB levels to define 4 groups
according to the relative contributions of central and go-
nadal dysfunction: Group A: primary hypogonadism
(FSH >15 IU/l and undetectable (<10 pg/ml) INB;
Group B: central hypogonadism (FSH <0.5 IU/l,
INB <10 pg/ml); Group C: partial gonadal and central
function (FSH 1.5–15 IU/l, INB >20 pg/ml); Group D: mild
central and severe gonadal dysfunction (FSH 1.5–15 IU/l,
INB< 20 pg/ml. In the last 2 groups FSH levels were
within the normal range but were inappropriately low for
the low INB.
Statistical analysis
One-way ANOVA was performed to analyze intergroup
differences in the levels of hormone levels and markers
of sexual maturation; Bonferroni correction was used as
a post-hoc test. Multiple t-tests, Chi-square and Fisher
Exact tests were used to analyze gender differences in
hormonal levels, the genetic subtypes and the male/
female ratio in the different groups. Pearson’s correla-
tions were calculated between the different parameters.
P< 0.05 was considered as statistically significant.
Results
As shown in Table 1, 10 patients (9 males) met the
established criteria for primary (hypergonadotrophic)
hypogonadism (group A) and 8 (4 males) for secondary
(central, hypogonadotrophic) hypogonadism (group B).
There were 9 individuals in Group C (4 males) and 8 in
group D (2 males). The difference in the sex ratios was
statistically significant (P= 0.04, χ2 test).
Analysis of FSH and INB levels in the groups we
defined, revealed highly significant differences among the
4 groups for both males (P< 0.0001, ANOVA), and
females (P< 0.0001 and P< 0.001 for FSH and INB
respectively) (Figure 1), as expected for the study design.
Similar differences in LH levels were found between the
groups (P< 0.001), however, the levels were within the
Table 1 Demographic and clinical data on the 35 participants with PWS: Group A: primary hypogonadism; Group B:
central hypogonadism; Group C: partial gonadal & central dysfunction; Group D: mild central and severe gonadal
dysfunction
Group A(n=10) Group B2(n=8) Group C (n=9) Group D3(n=8)
Males/Females4 9 / 1 4/ 4 4 / 5 2 / 6
Genetic subtype
DEL/UPD/IC
8 / 2 5 / 2 / 1 4 / 5 4 / 4
Age (y) (mean±SD)
Males 23.7±6.3 21.2±5.5 21.5±4.9 19.5±2.1
Females 17.4 24.0±2.7 24.2±4.9 23.2±5.7
Height (cm)
Males 154.0±8.2 152.0±5.3 155.6±9.5 151.5±4.2
Females 154 142.5±11.6 148.3±4.1 141.1±13.0
BMI (cm/kg2)
Males 26.2±3.8 36.6±4.7 35.3±17.2 28.4±8.1
Females 28.7 35.5±1.6 37.2±15.2 36.7±13.3
Pubic hair 1
Males 4.2±0.8 2.3±1.5 3.8±1.3 4.5±0.7
Females 3 4.0±0.0 4.6±0.5 3.0±1.7
Breast development 1 3 4.0±0.0 4.4±0.6 3.4±0.5
Penis length (cm) 8.2±1.7 5.3±0.3 8.5±3.7 7.3±1.8
Testes volume 1 1.7±0.9 1.5±1.0 2.6±1.3 1.5±0.7
1 Tanner stages (13, 14).
2 One man who was treated with testosterone for few months about 10 years before the study was excluded from the morphometric and sexual development
analysis. His penile length was 8 cm, PH Tanner stage 4 and testes Tanner stage 1.
3 One woman who has been treated with sequential estradiol and progestin (progyluton) for a few years before the study was excluded from the morphometric
and sexual development analysis. She had breast and PH Tanner stage 5.
4 P = 0.04 for the difference in the sex ration, χ2 test.
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group B who had very low levels of both FSH and LH.
INB levels were well below the normal range in the males
from each of the 4 groups, although the men in group C
had significantly higher levels, as per the study design. Only
the women in group C and one 17 year-old boy had INB
levels approaching the lower limit of the normal range.
Elevated LH and/or FSH levels, indicative of appropri-
ate hypothalamic-pituitary response to hypogonadism
(hypergonadotrophic hypogonadism), were found in 9/
19 (47%) of the males but in only one female (6%). In
addition, INB was below the fifth percentile for 18/19
males and below the 10th percentile in all males (18); in
females, INB levels were only moderately decreased (20)
(Figure 1). One male and one female in group B and one
male in group C had received growth hormone treat-
ment earlier in childhood.
Significant differences were also found among the males
groups in testosterone and AMH levels, but only AMH
showed significant differences after Bonferroni correction
(P=0.003). Similar to INB, testosterone levels were below
the normal range in all males; yet mean testosterone levels
in group C were higher than in the other groups. AMH
levels in males from group B were in the range of pre- orearly pubertal boys which are considerably higher than
during late puberty and adulthood in normal males
[22,23]. Interestingly, the males in the other groups had
almost normal AMH despite very low INB. In contrast,
almost all females had AMH levels within the normal
range (Figure 1).
Mean age, the genetic diagnoses, height, weight and
BMI, as well as pubertal staging were similar within the
groups, except for breast development in the females
(P = 0.04) and pubic hair Tanner stage in the males
(P = 0.04); however the differences did not reach statis-
tical significance after Bonferroni correction. In all males
penile length was near or below −2 SD [24,25].
In contrast to testosterone levels in the males, E2 levels
in the females were within the normal early follicular
stage range in most women from all 4 groups. Mean
androstenedione, DHEAS, SHBG, prolactin and TSH
levels were similar among the four groups.
No correlation was found between the various markers
of pubertal development (breast and pubic hair Tanner
stages) and any hormone level in females; however, in
males, penis length correlated significantly with testoster-
one levels (r = 0.625; P=0.004) and with testes Tanner stage
(r = 0.689; P=0.001) (Table 2).
Figure 1 Serum levels of LH, FSH, AMH and inhibin B (INB) in the four groups of PWS males and females, serum estradiol levels in
females and testosterone levels in males. Group A: primary hypogonadism; Group B: central hypogonadism; Group C: partial gonadal & central
dysfunction; Group D: mild central and severe gonadal dysfunction. Criteria for classifying patients in each group according to inhibin B and FSH
levels are described in “Results.” The grey bars represent the normal ranges. Among the 4 groups P< 0.0001 for the differences in FSH and INB,
P< 0.001 for the differences in LH and P< 0.01 for AMH. Among the males, P< 0.0001, P< 0.03 and P< 0.01 respectively for INB, testosterone
and AMH. Among the females, P< 0.001 for INB (ANOVA).
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androgens levels [androstenedione (r = 0.623; P< 0.01);
testosterone (r = 0.639; P< 0.01); DHEA-S (r = 0.757;
P< 0.0001)], LH and FSH levels (r = 0.636; P< 0.003 in
males and r=0.757 in females; P< 0.0001) and between an-
drogen levels in females (r=0.757-0.883; P< 0.0001, Table 2).
No correlation was found between the genetic subtype
and the degree of sexual maturation or between weight,
BMI or Tanner stage in both sexes. There was also no
correlation between pubic hair and breast or penis Tan-
ner stages or between age and sexual maturation.
Discussion
In a cohort of adolescents and adults with PWS, we char-
acterized four distinct patterns of gonadal dysfunctionbased on FSH and inhibin B levels: hypergonadotrophic
(primary gonadal) hypogonadism, hypogonadotrophic
(central/hypothalamic) hypogonadism, partial gonadal and
central dysfunction and mild central with severe gonadal
dysfunction. All our PWS males had immature genital
development and low serum testosterone. All of the
women had amenorrhea or oligomenorhea although
serum estradiol levels were in the normal early follicular
range. Although significant differences among the four
groups were observed for LH and in men, for testosterone
and AMH, we found FSH and INB basal levels to be the
most useful criteria for characterizing the type of hypo-
gonadism in our male and female PWS patients.
Reviews of PWS published as recently as 2011 maintain
the commonly held dogma that hypogonadism in PWS is
Table 2 Significant Pearson’s coefficient correlations
(r > 0.550; P<0.02) between the various clinical, hormonal
and sexual maturation parameters
Males Females
r p r p
LH-FSH 0.636 0.003 0.835 0.000
E2 - androstendione 0.623 0.01
E2 - T 0.639 0.008
T - penis length 0.625 0.004
E2 - DHEAS 0.757 0.000
DHEAS - androstenedione 0.757 0.000
T - androstenedione 0.853 0.000
T - DHEAS 0.883 0.000
SHBG - INB 0.693 0.003
BMI – penis length −0.690 0.001
BMI - PH −0.594 0.007
PH – penis length 0.635 0.003
Testes – penis length 0.663 0.002
Age - SHBG 0.785 0.000
E2 - height −0.598 0.014
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found that severe gonadal dysfunction was the major cause
of hypogonadism in 51% of our study population (groups
A+D), while severe, isolated gonadotropin deficiency was
found in only 23% (group B). These phenotypes showed
no correlation with genotype, age or BMI. Gonadal dys-
function, as indicated by INB levels (gender specific per-
centiles) was less severe in females. These gender
differences may explain the potential for fertility in women
with PWS [7,8] compared to the apparent lack of fertility
in all PWS men.
Hypogonadism in PWS is almost universal, although
clinical manifestations are variable [26]. Spontaneous
menstruation does occur in some PWS women and rare
pregnancies have been reported. In a population-based
study Butler et al [27] reported that 8 of 16 females, over
11 years of age had a history of at least one instance of
spontaneous vaginal bleeding, without prior administra-
tion of sex hormones. Menarche occurred late (at age of
20 ± 7 years) [27]. In our group spontaneous menarche
occurred only in 25% of the women (4/16) at age15–
30 years. Vaginal bleeding in obese women does not ne-
cessarily indicate ovulation or ovarian steroid secretion,
since aromatization of adrenal steroids to estrogens in
adipose tissue may trigger pseudo-pubertal development,
endometrial estrogenisation and breakthrough bleeding.
The significant correlation between estradiol and andro-
gens levels found in our females with PWS, including
the correlation with the exclusively adrenal steroid
DHEA-S, supports this concept.Five pregnancies have been reported in three women
with genetically documented PWS [7,8]. Seven more preg-
nancies in two women in whom PWS was diagnosed by
clinical criteria only, were reported before the genetics of
PWS had been delineated [28,29]. There are, however, no
known physical characteristics or hormonal patterns which
have been shown to predict which PWS are potentially fer-
tile. In two women in our study, ages 21.5 and 26 years,
INB levels, 47.3 and 53 pg/ml were consistent with a possi-
bility of fertility [20,30]. We suggest measuring INB in all
adolescents and women with PWS, to assess fertility po-
tential and to consider contraception when appropriate.
In normal women, both INB and AMH can be used to
assess fertility potential, although AMH is considered to
be more reliable [21,30,31]. However, despite the highly
significant differences in INB levels between our groups,
no inter-group differences could be found in AMH levels
in the females (Figure 1). In our previous publications,
we showed that both males and females with PWS had a
unique pattern of gonadal dysfunction characterized by
extremely low or undetected INB along with normal
AMH levels [11,12,32]. Thus, in PWS, INB appears to be
the most reliable marker of gonadal function and prob-
ably of fertility potential.
Hypogonadotrophic hypogonadism was more profound
in females: adequate hypothalamic response to the pri-
mary gonadal defect (hypergonadotrophic hypogonad-
ism) was found in only one female (6%) in our study, but
was documented in 47% of the males. Eiholzer et al
[33,34] showed that primary testicular dysfunction con-
tributes to the hypogonadism in PWS male infants and
boys. Radicioni et al [13] characterized the hormonal
profiles of 24 pubertal PWS males based on LH, FSH, in-
hibin B and testosterone to hypogonadotropic hypo-
gonadism of central origin for LH (with low secretion of
testosterone) and/or FSH(with low secretion of inhibin
B), early primary testicular dysfunction secondary to Ser-
toli cells damage (elevated FSH and low inhibin B) and a
combined form of hypogonadism . They did not present
data on PWS females.
The dissimilarity, in hypothalamic-pituitary function, be-
tween males and females with PWS might be explained by
the divergence in the regulation of FSH secretion between
normal males and females. In both sexes, FSH secretion is
stimulated by GnRH and inhibited by inhibin and, in
women, also by estrogens. The normal range of INB levels
is higher in males than females at all ages [18-20,35-37];
estradiol levels in women with normal ovarian function
are much higher than in men while FSH levels are similar
in both sexes. As we proposed previously [12], we assume
that the common cause of hypogonadism in most PWS
patients, both males and females, is related to a unique de-
fect in INB secretion. The lack of negative feedback by
INB was associated with higher FSH levels in males than
Gross-Tsur et al. Reproductive Biology and Endocrinology 2012, 10:39 Page 6 of 7
http://www.rbej.com/10/1/39in females, in whom estradiol and estrone originates from
the abundant adipose tissue, and may contribute to the
negative feedback on GnRH and FSH secretion.
Guidelines for hormonal replacement therapy in indi-
viduals with PWS may need to be tailored individually
depending on the specific hypogonadal phenotype. As-
sessment of specific hormonal data, including INB, to-
gether with consideration of other parameters such as
BMI, may enable us to tailor specific HRT for women
with PWS. Cyclic progesterone may be indicated for
those with amenorrhea and normal estradiol levels, par-
ticularly in obese women. Progestin would overcome the
unopposed estrogenic effect on the endometrium and will
prevent endometrial hyperplasia and cancer. Combined es-
trogen/progesterone treatment or bi-phosphonates is sug-
gested for women with amenorrhea and low estradiol
levels, particularly those with low or normal BMI. These
will prevent osteoporosis and other consequences of pro-
longed hypoestrogenism. The possibility that PWS women
might need contraception should be considered and dis-
cussed with the patient or her guardians if INB is greater
than 20 pg/ml. Such INB level indicates partial ovarian
function and raises the possibility of fertility. Since all
males have low testosterone levels, testosterone treatment
should be considered for those from each of the four
groups, although behavioral changes should be monitored.
A prospective study of HRT for adolescents and adults with
PWS including effects on osteoporosis, body image, behav-
ior, and quality of life is needed.
Conclusions
Analysis of FSH and INB serum levels allowed us to
characterize four distinct phenotypes of hypogonadism
in PWS adolescents and adults ranging from primary
gonadal to central hypogonadism. Severe primary go-
nadal dysfunction in combination with a wide range of
gonadotropin secretion was the major cause of hypo-
gonadism in most of the cohort. Severe, isolated go-
nadotropin deficiency was found in less than a quarter
of our population. These phenotypes showed no correl-
ation with genotype, age or BMI. Hypergonadotrophic
hypogonadism was more pronounced in males. Hormo-
nal replacement therapy should be tailored to the spe-
cific phenotype. Measurement of INB is recommended
for assessing the possibility of fertility in women and the
need for contraception. Further longitudinal studies are
needed to document whether the individual hypo-
gonadal phenotype is consistent during their life span.
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